Last update April 29, 2022
Very Low Risk
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
M01AE03; M02AA10 is Ketoprofen in ATC Code/s.Is written in other languages:
M01AE03; M02AA10 belongs to these groups or families:
Main tradenames from several countries containing M01AE03; M02AA10 in its composition:
|Oral Bioavail.||90 (Derm: 5%)||%|
|Tmax||0.5 - 4||hours|
|T½||1.5 - 4||hours|
|Theoretical Dose||0.009 (0.003 a 0.021)||mg/Kg/d|
|Relative Dose||0.3 (0.14 - 0.48)||%|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Ketoprofen is a non-steroidal anti-inflammatory drug (NSAID). Oral, rectal, intramuscular, intravenous and topical administration every 6 to 12 hours.
It is excreted in breastmilk in clinically negligibe amounts (Jacqz-Aigrain 2007) and expert authors consider it compatible with breastfeeding (Hale, Davanzo 2014, Jacqz-Aigrain 2007, Janssen 2000, Nice 2000). Its high percentage of protein binding explains the very small transfer to milk observed.
In a French pharmacovigilance study, several possible cases, unconfirmed, were found of the implication of ketoprofen in certain adverse effects in the infant (Soussan 2014). Its pharmacokinetics makes its involvement unlikely.
Most non-steroidal anti-inflammatories may increase jaundice, so it is preferable to avoid them during the neonatal period in mothers of infants with jaundice. (Janssen 2000)
TOPICAL USE: The small dose and the low plasma absorption of most topical dermatological preparations make transfer to breastmilk in significant amounts unlikely. Dermal bioavailability is 5%. (AEMPS 2016)
See below the information of this related product: